金吾财讯 | 国金证券发研指，巨子生物(02367)近日官网公示，其骨修复材料获批三类医疗器械，符合此前招股书24Q4拿证预期。1）适应症：牙颌骨、牙槽骨缺损填充和修复；2）优势：既能快速塑形不塌陷起到支撑作用，又具有引导骨再生的高效修复作用；3）成分：无机成分为羟基磷灰石颗粒，有机成分为大分子多糖。
该行表示，妆品持续完善多单品矩阵，医美明年预期落地。考虑双十一线上表现亮眼，上调公司盈利预测，预计24-26年经调整净利润20.9/25.5/30.6亿元（前值20.3/25.2/30.1亿元）、同增43%/22%/20%，归母净利润20/24.6/29.7亿元，同增38%/23%/21%、对应PE25/20/17倍，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.